

List of publications [Impact Factor 2012]

1. **T. Tselios**, L. Probert, G. Kollias, E. Matsoukas, P. Roumelioti, K. Alexopoulos, G. Moore, J. Matsoukas*. Design and synthesis of small semi-mimetic peptides with Immunomodulatory activity based on Myelin Basic Protein (MBP). *Amino Acids*, **1998**, 14: 333-341. [IF: 3.914]
2. K. Alexopoulos, J. Matsoukas*, **T. Tselios**, P. Roumelioti, T. Mavromoustakos, K. Holada. A Comparative SAR Study of Thrombin Receptor Derived non-peptide Mimetics: Importance of Phenyl/Guanidino Proximity for Activity. *Amino Acids*, **1998**, 15: 211-220. [IF: 3.914]
3. J. Pires, **T. Tselios**, J. Matsoukas, G. Moore*. Role of Myelin Basic Protein Epitope MBP₇₄₋₈₅ in Experimental Autoimmune Encephalomyelitis: Elaboration of Agonist and Antagonist Motifs. *Drug Development Research*, **1999**, 48: 1-5. [IF: 1.193]
4. **T. Tselios**, L. Probert, I. Daliani, E. Matsoukas, A. Troganis, I. Gerothanasis, T. Mavromoustakos, G. Moore, J. Matsoukas*. Design and Synthesis of a Potent Cyclic Analogue of the Myelin Basic Protein Epitope MBP₇₂₋₈₅: Importance of the Ala⁸¹ Carboxyl Group and of a Cyclic Conformation for Induction of Experimental Allergic Encephalomyelitis (E.A.E.). *J. Med. Chem.*, **1999**, 42, 7:1170-1177. [IF: 5.614]
5. P. Roumelioti, **T. Tselios**, K. Alexopoulos, T. Mavromoustakos, A. Kolocouris, G. Moore, J. Matsoukas*. Structural Comparison Between Type I and type II Antagonists: Possible Implications in the Drug Design of AT1 Antagonists. *Bioorg. Med. Chem. Lett.*, **2000**, 10: 1-4. [IF: 2.338]
6. **T. Tselios**, I. Daliani, L. Probert, S. Deraos, E. Matsoukas, S. Roy, J. Pires, G. Moore, J. Matsoukas*. Treatment of Experimental Allergic Encephalomyelitis (EAE) Induced by Guinea Pig Myelin Basic Protein Epitope 72-85 with a Human MBP₈₇₋₉₉ Analogue and Effects of Cyclic Peptides. *Bioorg. Med. Chem.*, **2000**, 8: 1903-1909. [IF: 2.903]
7. **T. Tselios**, I. Daliani, S. Deraos, S. Thymianou, E. Matsoukas, A. Troganis, I. Gerothanassis, A. Mouzaki, T. Mavromoustakos, L. Probert, J. Matsoukas*. Treatment of Experimental Allergic Encephalomyelitis (EAE) by a Rationally Designed Cyclic Analogue of Myelin Basic Protein (MBP) Epitope 72-85. *Bioorg. Med. Chem. Lett.*, **2000**, 10: 2713-2717. [IF: 2.338]
8. **T. Tselios**, V. Apostolopoulos, I. Daliani, S. Deraos, S. Grdadolnik, T. Mavromoustakos, M. Melachrinou, S. Thymianou, L. Probert, A. Mouzaki, J. Matsoukas*. Antagonistic Effects of Human Cyclic MBP₈₇₋₉₉ Altered Peptide Ligands in Experimental Allergic Encephalomyelitis and Human T-Cell Proliferation. *J. Med. Chem.*, **2002**, 45, 275-283. [IF: 5.614]
9. A.G. Tzakos, P. Fuchs, N.A. van Nuland, A. Troganis, **T. Tselios**, S. Deraos, J. Matsoukas, I.P. Gerothanassis*, A.M. Bonvin. NMR and molecular dynamics studies of an autoimmune myelin basic protein peptide and its antagonist: structural implications for the MHC II (I-Au)-peptide complex from docking calculations. *Eur. J. Biochem.*, **2004**, 271(16): 3399-3413. [IF: 4.250]
10. A. Mouzaki*, **T. Tselios**, P. Papathanassopoulos, I. Matsoukas, K. Chatzantoni. Immunotherapy for Multiple Sclerosis: Basic insights for new clinical strategies. *Current Neurovascular Research*, **2004**, 1(4): 325-340. [IF: 2.844]

11. J. Matsoukas*, V. Apostolopoulos, H. Kalbacher, A.M. Papini, **T. Tselios**, K. Chantzantoni, T. Biagioli, F. Lolli, S. Deraos, P. Papathanassopoulos, A. Troganis, E. Mantzourani, T. Mavromoustakos, A. Mouzaki*. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. *J. Med. Chem.*, **2005**, 10, 48(5):1470-1480. [IF: 5.614]
12. A. Tzakos, P. Kursula, V. Theodorou, **T. Tselios**, C. Svarnas, J. Matsoukas, A. Troganis, V. Apostolopoulos, I. Gerothanassis*. Structure and Function of the Myelin Proteins: Current Status and Perspectives in Relation to Multiple Sclerosis. *Cur. Med. Chem.*, **2005**, 12, 13, 1569-1587. [IF: 4.07]
13. N. Grigoriadis*, **T. Tselios**, S. Deraos, A. Orologas, G. Deraos, J. Matsoukas, I. Mavromatis, I. Milonas. Animal models of central nervous system immune-mediated diseases: Therapeutic interventions with Bioactive Peptides and Mimetics. *Cur. Med. Chem.*, **2005**, 12, 13, 1513-1519. [IF: 4.07]
14. E.D. Mantzourani, T.M. Mavromoustakos, J.A. Platts, J.M. Matsoukas, **T.V. Tselios***. Structural Requirements for Binding of Myelin Basic Protein (MBP) Peptides to MHC II: Effects in Immune Regulation. *Cur. Med. Chem.*, **2005**, 12, 13, 1569-1587. [IF: 4.07]
15. **T.V. Tselios**, F.N. Lamari, I. Karathanasopoulou, M. Katsara, V. Apostolopoulos, G.A. Pietersz, J.M. Matsoukas, N.K. Karamanos*. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. *Anal. Biochem.*, **2005**, 1, 347(1):121-128. [IF: 2.582]
16. M.K. Keramida*, **T. Tselios**, E. Mantzourani, K. Papazisis, T. Mavromoustakos, C. Klaussen, G. Agelis, S. Deraos, I. Friligou, H. Habibi, J. Matsoukas*. Design, synthesis, and molecular modeling of a novel amide-linked cyclic GnRH analogue cyclo(4-9)[Lys4,D-Trp6,Glu9]GnRH: stimulation of gonadotropin gene expression. *J. Med. Chem.*, **2006**, 49(1): 105-110. [IF: 5.614]
17. M. Katsara, **T. Tselios**, S. Deraos, G. Deraos, J. Matsoukas, V. Apostolopoulos*. Round and round we go: cyclic peptides in disease. *Cur. Med. Chem.*, **2006**, 13(19): 2221-2232. [IF: 4.07]
18. E. Mantzourani, **T. Tselios**, S.G. Grdadolnik, A. Brancale, J. Matsoukas, T. Mavromoustakos*. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg⁹¹, Ala⁹⁶]MBP₈₇₋₉₉. *Journal of Molecular Graphics and Modelling*, **2006**, 25/1, 17-29. [IF: 2.325]
19. E.D. Mantzourani, **T.V. Tselios***, S. Golič Grdadolnik; J.A. Platts, A. Brancale, G. Deraos, J.M. Matsoukas, T.M. Mavromoustakos*. Comparison of Proposed Putative Active Conformations of Linear Altered Peptide Ligands of Myelin Basic Protein Epitope 87-99 by Spectroscopic and Modelling studies: The Role of Position 91 and 96 in T-cell Receptor Activation. *J. Med. Chem.*, **2006**, 49, 6683-6691. [IF: 5.614]
20. E.D. Mantzourani, J.A. Platts, A. Brancale, T.M. Mavromoustakos, **T.V. Tselios***. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: Triggering of immune response. *Journal of Molecular Graphics and Modelling*, **2007**, 26(2): 471-481. [IF: 2.325]

21. Z. Spyralanti, G.A. Dalkas, G.A. Spyroulias*, E.D. Mantzourani, T. Mavromoustakos, I. Friligou, J.M. Matsoukas, **Tselios TV***. Putative Bioactive Conformations of Amide Linked Cyclic Myelin Basic Protein Peptide Analogues Associated with Experimental Autoimmune Encephalomyelitis. *J. Med. Chem.*, **2007**, 29, 50(24):6039-6047. [IF: 5.614]
22. **T. Tselios***, K. Kelaidonis, A. Resvani, K. Prousalis, J. Matsoukas, T. Tsegenidis*. Solid Phase Synthesis of a Glycopeptide analogue using the acid sensitive 4-Methoxybenzhydryl bromide resin. *Protein & Peptide Letters*, **2008**, 15(1):1-5. [IF: 1.994]
23. G. Agelis, N. Tzioumaki, **T. Tselios**, T. Botić, A. Cencic, D. Komiotis*. Synthesis and molecular modelling of unsaturated exomethylene pyranonucleoside analogues with antitumor and antiviral activities. *Eur. J. Med. Chem.*, **2008**, 43(7): 1366-1375. [IF: 3.499]
24. E.D. Mantzourani, K. Blokar, **T.V. Tselios**, J.M. Matsoukas, J.A. Platts, T.M. Mavromoustakos, S.G. Grdadolnik*. A combined NMR and molecular dynamics simulation study to determine the conformational properties of agonists and antagonists against experimental autoimmune encephalomyelitis. *Bioorg. Med. Chem.*, **2008**, 1, 16(5): 2171-2182. [IF: 2.903]
25. Z.D. Sofianos, T. Katsila, N. Kostomitsopoulos, V. Balafas, J. Matsoukas, **T. Tselios**, C. Tamvakopoulos*. In vivo evaluation and in vitro metabolism of leuprolide in mice-mass spectrometry-based biomarker measurement for efficacy and toxicity. *J. Mass. Spectrom.*, **2008**, 43(10): 1381-1392. [IF: 3.214]
26. M. Katsara, E. Yuriev, P.A. Ramsland, G. Deraos, **T. Tselios**, J. Matsoukas, V. Apostolopoulos*. Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2. *Mol. Immunol.*, **2008**, 45(13): 3661-3670. [IF: 2.645]
27. M. Katsara, G. Deraos, **T. Tselios**, J. Matsoukas, V. Apostolopoulos*. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. *J. Med. Chem.*, **2008**, 10, 51(13): 3971-3978. [IF: 5.614]
28. M. Katsara, E. Yuriev, P.A. Ramsland, G. Deraos, **T. Tselios**, J. Matsoukas, V. Apostolopoulos*. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. *J. Neuroimmunol.*, **2008**, 30, 200(1-2): 77-89. [IF: 3.033]
29. E. Mantzourani, D. Laimou, M.T. Matsoukas, **T. Tselios***. Peptides as therapeutic agents or drug leads for autoimmune, hormone dependent and cardiovascular diseases. *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, **2008**, 7, 294-306.
30. K. Gkountelias, **T. Tselios**, M. Venihaki, G. Deraos, I. Lazaridis, O. Rassouli, A. Gravanis, G. Liapakis*. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. *Mol. Pharmacol.*, **2009**, 75(4): 793-800. [IF: 4.411]
31. M. Katsara, G. Deraos, **T. Tselios**, M.T. Matsoukas, I. Friligou, J. Matsoukas, V. Apostolopoulos*. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis. *J. Med. Chem.*, **2009**, 8, 52(1): 214-218. [IF: 5.614]

32. G. Deraos, K. Chatzantoni, M.T. Matsoukas, **T. Tselios**, S. Deraos, M. Katsara, P. Papathanasopoulos, D. Vynios, V. Apostolopoulos*, A. Mouzaki*, J. Matsoukas* Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. *J. Med. Chem.*, **2008**, 25, 51(24): 7834-7842. [IF: 5.614]
33. Z. Spyranti, **T. Tselios**, G. Deraos, J. Matsoukas, G.A. Spyroulias*. NMR structural elucidation of myelin basic protein epitope 83-99 implicated in multiple sclerosis. *Amino Acids*, **2010**, (38)3: 926-936. [IF: 3.914]
34. M. Katsara, E. Yuriev, P.A. Ramsland, **T. Tselios**, G. Deraos, A. Lourbopoulos, N. Grigoriadis, J. Matsoukas, V. Apostolopoulos*. Altered peptide ligands of myelin basic protein (MBP87-99) conjugated to reduced mannan modulate immune responses in mice. *Immunology*, **2009**, 128, 521-533. [IF: 3.705]
35. M. Emmanouil, E. Taoufik, V. Tseveleki, S.S. Vamvakas, **T. Tselios**, M. Karin, H. Lassmann, L. Probert*. Neuronal I κ B kinase β protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the CNS. *The Journal of Immunology*, **2009**, 15, 183(12): 7877-7889. [IF: 5.520]
36. DK. Laimou, M. Katsara, M.T. Matsoukas, V. Apostolopoulos, AN. Troganis, **TV. Tselios***. Structural elucidation of Leuprolide and its analogues in solution: insight into their bioactive conformation. *Amino Acids*, **2010**, 39(5): 1147-1160. [IF: 3.914]
37. I. Friligou, E. Papadimitriou, D. Gatos, J. Matsoukas, **T. Tselios***. Microwave-Assisted Solid-Phase Peptide Synthesis of the 60-110 Domain of Human Pleiotrophin (hPTN) on 2-Chlorotriptyl Resin. *Amino Acids*, **2011**, 40(5): 1431-1440. [IF: 3.914]
38. A. Aggelis, A. Resvani, M-T. Matsoukas, **T. Tselios**, K. Kelaidonis, D. Kalavrizioti, D. Vlahakos, J. Matsoukas*. Towards non-peptide ANG II AT1 receptor antagonists based on urocanic acid: rational design, synthesis and biological evaluation. *Amino Acids*, **2011**, 40(2): 411-420. [IF: 3.914]
39. T. Katsila, E. Balafas, G. Liapakis, P. Limonta, M. Montagnani Marelli, K. Gkountelias, **T. Tselios**, N. Kostomitsopoulos, J. Matsoukas, C. Tamvakopoulos*. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer. *J. Pharmacol. Exp. Ther.*, **2011**, 336(3): 613-623. [IF: 3.891]
40. M-T. Matsoukas, P. Zoumpoulakis, **T. Tselios***. Conformational analysis of aliskiren, a potent renin inhibitor, using high-resolution nuclear magnetic resonance and molecular dynamics simulations. *J. Chem. Inf. Model.*, **2011**, 26, 51(9): 2386-2397. [IF: 4.304]
41. C. Potamitis, M.T. Matsoukas, **T. Tselios***, T. Mavromoustakos*, S. Golič Grdadolnik*. Conformational analysis of the MBP(83-99) (Phe (91)) and MBP (83-99) (Tyr (91)) peptide analogues and study of their interactions with the HLA-DR2 and human TCR receptors by using Molecular Dynamics. *J. Comput. Aided Mol. Des.*, **2011**, 25(9): 837-853. [IF: 3.172]

42. E. Taoufik, V. Tseveleki, S.Y. Chu, **T. Tselios**, M. Karin, H. Lassmann, D.E. Szymkowski, L. Probert*. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. *Brain*, **2011**, 134(9): 2722-2735. [IF: 9.915]
43. D. Laimou, E. Lazoura, A.N. Troganis, M-T. Matsoukas, S.N. Deraos, M. Katsara, J. Matsoukas, V. Apostolopoulos, **T.V. Tselios***. Conformational studies of immunodominant myelin basic protein 1-11 analogues using NMR and molecular modelling. *J. Comput. Aided Mol. Des.*, **2011**, 25(11): 1019-1032. [IF: 3.172]
44. D. Laimou, T. Katsila, J. Matsoukas, A. Schally, K. Gkountelias, G. Liapakis, C. Tamvakopoulos, **T. Tselios***. Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties. *Eur. J. Med. Chem.*, **2012**, 58: 237-247. [IF: 3.499]
45. M.T. Matsoukas, A. Cordoní, S. Ríos, L. Pardo, **T. Tselios***. Ligand binding determinants for angiotensin II type 1 receptor from computer simulations. *J. Chem. Inf. Model.*, **2013**, 25, 53(11): 2874-2883. [IF: 4.304]
46. I. Friligou, F. Rizzolo, F. Nuti, **T. Tselios***, M. Evangelidou, M. Emmanouil, M. Karamita, J. Matsoukas, M. Chelli, P. Rovero, A.M. Papini*. Divergent and convergent synthesis of polymannosylated dibranched antigenic peptide of the immunodominant epitope MBP(83-99). *Bioorg. Med. Chem.*, **2013**, 1, 21(21): 6718-6725. [IF: 2.903]
47. G. Agelis*, K. Kelaidonis, A. Resvani, D. Kalavrizioti, M.E. Androutsou, P. Plotas, D. Vlahakos, C. Koukoulitsa, **T. Tselios**, T. Mavromoustakos, J. Matsoukas*. Facile and efficient syntheses of a series of N-benzyl and N-biphenylmethyl substituted imidazole derivatives based on (E)-urocanic acid, as angiotensin II AT1 receptor blockers. *Molecules*, **2013**, 27, 18(7): 7510-7532. [IF: 2.428]
48. D. Ntountaniotis*, G. Agelis*, A. Resvani, M. Halabalaki, G. Liapakis, K. Spyridaki, S. Golič Grdadolnik, F. Merzel, S. Kostidis, C. Potamitis, **T. Tselios**, J. Matsoukas, L.A. Skaltsounis, T. Mavromoustakos*. An Efficient Synthetic Method and Theoretical Calculations of Olmesartan Methyl Ether. Study of Biological Function of AT1 Antagonism. *Comb. Chem. High Throughput Screen.*, **2014**, 17(8): 652-662. [IF: 2.0]
49. D. Ntountaniotis*, T. Kellici, A. Tzakos, P. Kolokotroni, **T. Tselios**, J. Becker-Baldus, C. Glaubitz, S. Lin, A. Makriyannis, T. Mavromoustakos*. The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan. *Biochim. Biophys. Acta.*, **2014**, 1838(10), 2439-2450. [IF: 3.833]
50. M. Katsara, S. Deraos, **T. Tselios**, G.A. Pietersz, J. Matsoukas, V. Apostolopoulos*. Immune responses of linear and cyclic PLP₁₃₉₋₁₅₁ mutant peptides in SJL/J mice. *Immunotherapy*, **2014**, 6(6): 709-724. [IF: 2.393]
51. **T. Tselios***, M. Aggelidakis, A. Tapeinou, V. Tseveleki, I. Kanistras, D. Gatos, J. Matsoukas*. Rational design and synthesis of altered peptide ligands based on human myelin oligodendrocyte glycoprotein 35-55 epitope: inhibition of chronic experimental autoimmune encephalomyelitis in mice. *Molecules*, **2014** 19(11): 17968-17984. [IF: 2.428]
52. S. Day, **T. Tselios**, M.E. Androutsou, A. Tapeinou, I. Friligou, L. Stojanovska, J. Matsoukas, V. Apostolopoulos*. Synthesis and immunogenicity of mannan conjugates of linear and cyclic altered

peptide ligands of myelin basic protein (MBP83-99) epitope: novel immunotherapeutics against Multiple Sclerosis. *Front. Immunol.*, **2015**, Apr7; 6: 136.

53. V. Tseveleki, **T. Tselios***, I. Kanistras, O. Koutsoni, M. Karamita, S.S. Vamvakas, V. Apostolopoulos, E. Dotsika, J. Matsoukas, H. Lassmann, L. Probert*. Immunotherapy of autoimmune encephalomyelitis using mannan-conjugated peptides to target antigen-presenting cells: A pre-clinical study in mice. *Exp. Neurol.*, **2015**, 267: 254-267. [IF: 4.645]
54. M. Ieronymaki, M.E. Androutsou, A. Pantelia, I. Friligou, M. Crisp, K. High, K. Penkman, D. Gatos, **T. Tselios***. Use of the 2-chlorotriyl chloride resin for microwave-assisted solid phase peptide synthesis. *Biopolymers*, **2015**, 104(5): 506-14. [IF: 2.879]
55. G. Deraos, M. Rodi, H. Kalbacher, K. Chatzantoni, F. Karagiannis, L. Synodinos, P. Plotas, A. Papalois, N. Dimisianos, P. Papathanasopoulos, D. Gatos, **T. Tselios**, V. Apostolopoulos, A. Mouzaki, J. Matsoukas*. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis. *Eur. J. Med. Chem.*, **2015**, 101: 13-23. [IF: 3.499]
56. G.G. Kordopati, **T.V. Tselios**, T. Kellici, F. Merzel, T. Mavromoustakos, S.G. Grdadolnik*, G.M. Tsigoulis*. A novel synthetic luteinizing hormone-releasing hormone (LHRH) analogue coupled with modified β -cyclodextrin: insight into its intramolecular interactions. *Biochim. Biophys. Acta.*, **2015**, 1850(1): 159-168. [IF: 3.848]
57. A. Tapeinou, M.E. Androutsou, K. Kyrtata, A. Vlamis-Gardikas*, V. Apostolopoulos, J. Matsoukas, **T. Tselios***. Conjugation of a peptide to mannan and its confirmation by tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis. *Anal. Biochem.*, **2015**, 15, 485: 43-45. [IF: 2.582]
58. A. Tapeinou, M.T. Matsoukas, C. Simal, **T. Tselios***. Review cyclic peptides on a merry-go-round; towards drug design. *Biopolymers*, **2015**, 104(5):453-461. [IF: 2.879]